Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 02, 2026 09:05 ET | Source: Myriad Genetics, Inc.

New Large-Scale Meta-Analysis Demonstrates Strong Prognostic Performance of Myriad’s Prolaris® Biopsy Test in Localized Prostate Cancer

New published data shows Prolaris Biopsy Test adds significant prognostic information beyond conventional clinical risk categories for prostate cancer.
July 01, 2026 16:05 ET | Source: Candel Therapeutics

Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEEDHAM, Mass., July 01, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal...
June 30, 2026 07:30 ET | Source: FocalTherics (TM)

FocalTherics™ Announces Successful Launch of First Commercial Endometriosis Focal One® Program in Europe with Treatment of Initial Patients

FocalTherics™ Announces Successful Launch of First Commercial Endometriosis Focal One® Program in Europe with Treatment of Initial Patients AUSTIN, Texas, June 30, 2026 (GLOBE NEWSWIRE) -- ...
June 25, 2026 10:06 ET | Source: OTraces, Inc.

OTraces Awarded $2 Million Florida Grant to Advance Non‑Invasive, High‑Accuracy Prostate Cancer Detection

OTraces awarded $2 Million Florida Department of Health grant to validate its proteomic blood test to reduce unnecessary prostate biopsies.
June 22, 2026 17:00 ET | Source: A3P Biomedical

Pioneering screening test offers potential to find more aggressive prostate cancers

Annals of Internal Medicine publishes study showing potential benefits of Stockholm3 in identifying patients with aggressive prostate cancer.
June 16, 2026 07:30 ET | Source: FocalTherics (TM)

FocalTherics™ Expands Access to Focal One® Robotic HIFU for Veterans with Prostate Cancer through Agreement with MellingMedical

FocalTherics™ Expands Access to Focal One® Robotic HIFU for Veterans with Prostate Cancer through Agreement with MellingMedical AUSTIN, Texas, June 16, 2026 (GLOBE NEWSWIRE) -- FocalTherics...
June 11, 2026 03:04 ET | Source: Curium

Curium Group, PeptiDream and PDRadiopharma Announce Completion of Patient Dosing in Clinical Trial of 64Cu-PSMA-I&T for Prostate Cancer in Japan

Completion of patient dosing in the registrational Phase 2 clinical trial for 64Cu-PSMA-I&T - a PET radiopharmaceutical targeting prostate-specific membrane antigen (PSMA) expressed on prostate...
June 03, 2026 08:30 ET | Source: Alpha Tau Medical Ltd.; Tolmar Inc.

Alpha Tau and Tolmar Announce Strategic Collaboration to Bring Alpha DaRT® Therapy to U.S. Urological Cancer Patients

Alpha Tau and Tolmar Announce Strategic Collaboration to Bring Alpha DaRT® Therapy to U.S. Urological Cancer Patients
June 01, 2026 16:05 ET | Source: Candel Therapeutics

Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEEDHAM, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal...
June 01, 2026 02:00 ET | Source: Curium

Curium Announces a Strategic Investment of Over €32 million in Saclay, France

Curium’s strategic investment of over €32 million will establish a European production line for 177Lu-PSMA-I&T, a therapeutic agent for patients with metastatic castration-resistant prostate...